These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 23687783)

  • 21. RPN2 gene confers docetaxel resistance in breast cancer.
    Honma K; Iwao-Koizumi K; Takeshita F; Yamamoto Y; Yoshida T; Nishio K; Nagahara S; Kato K; Ochiya T
    Nat Med; 2008 Sep; 14(9):939-48. PubMed ID: 18724378
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanisms of drug resistance in cancer chemotherapy.
    Luqmani YA
    Med Princ Pract; 2005; 14 Suppl 1():35-48. PubMed ID: 16103712
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tanshinone IIA acts via p38 MAPK to induce apoptosis and the down-regulation of ERCC1 and lung-resistance protein in cisplatin-resistant ovarian cancer cells.
    Jiao JW; Wen F
    Oncol Rep; 2011 Mar; 25(3):781-8. PubMed ID: 21165580
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Melanoma and search for therapeutic targets].
    de la Fouchardière A
    Ann Pathol; 2011 Nov; 31(5 Suppl):S123-4. PubMed ID: 22054449
    [No Abstract]   [Full Text] [Related]  

  • 25. A gene expression database for the molecular pharmacology of cancer.
    Scherf U; Ross DT; Waltham M; Smith LH; Lee JK; Tanabe L; Kohn KW; Reinhold WC; Myers TG; Andrews DT; Scudiero DA; Eisen MB; Sausville EA; Pommier Y; Botstein D; Brown PO; Weinstein JN
    Nat Genet; 2000 Mar; 24(3):236-44. PubMed ID: 10700175
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Functional drug-gene interactions in lung cancer.
    Smida M; Nijman SM
    Expert Rev Mol Diagn; 2012 Apr; 12(3):291-302. PubMed ID: 22468819
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Overexpression of miR-200c induces chemoresistance in esophageal cancers mediated through activation of the Akt signaling pathway.
    Hamano R; Miyata H; Yamasaki M; Kurokawa Y; Hara J; Moon JH; Nakajima K; Takiguchi S; Fujiwara Y; Mori M; Doki Y
    Clin Cancer Res; 2011 May; 17(9):3029-38. PubMed ID: 21248297
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lipid raft modulation by Rp1 reverses multidrug resistance via inactivating MDR-1 and Src inhibition.
    Yun UJ; Lee JH; Koo KH; Ye SK; Kim SY; Lee CH; Kim YN
    Biochem Pharmacol; 2013 May; 85(10):1441-53. PubMed ID: 23473805
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Changing pathology with changing drugs: skin cancer.
    Karpova MB; Barysch MJ; Zipser MC; Schönewolf N; French LE; Dummer R
    Pathobiology; 2011; 78(2):61-75. PubMed ID: 21677470
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Understanding resistance to targeted cancer drugs through loss of function genetic screens.
    Berns K; Bernards R
    Drug Resist Updat; 2012 Oct; 15(5-6):268-75. PubMed ID: 23142522
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecularly targeted therapy for melanoma: current reality and future options.
    Becker JC; Kirkwood JM; Agarwala SS; Dummer R; Schrama D; Hauschild A
    Cancer; 2006 Nov; 107(10):2317-27. PubMed ID: 17039502
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The emerging role of CXC chemokines and their receptors in cancer.
    Vinader V; Afarinkia K
    Future Med Chem; 2012 May; 4(7):853-67. PubMed ID: 22571611
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cancer and natural selection.
    Fillon M
    J Natl Cancer Inst; 2012 Dec; 104(23):1773-4. PubMed ID: 23213180
    [No Abstract]   [Full Text] [Related]  

  • 34. "Overcoming breast cancer drug resistance with mTOR inhibitors". Could it be a myth or a real possibility in the short-term future?
    Margariti N; Fox SB; Bottini A; Generali D
    Breast Cancer Res Treat; 2011 Aug; 128(3):599-606. PubMed ID: 20945086
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A synthetic coumarin (4-methyl-7 hydroxy coumarin) has anti-cancer potentials against DMBA-induced skin cancer in mice.
    Bhattacharyya SS; Paul S; Mandal SK; Banerjee A; Boujedaini N; Khuda-Bukhsh AR
    Eur J Pharmacol; 2009 Jul; 614(1-3):128-36. PubMed ID: 19393233
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting mTOR: something old, something new.
    Garber K
    J Natl Cancer Inst; 2009 Mar; 101(5):288-90. PubMed ID: 19244168
    [No Abstract]   [Full Text] [Related]  

  • 37. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
    Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
    Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rational targeting of Notch signaling in cancer.
    Rizzo P; Osipo C; Foreman K; Golde T; Osborne B; Miele L
    Oncogene; 2008 Sep; 27(38):5124-31. PubMed ID: 18758481
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Responses to targeted therapies: lung cancer].
    Brambilla E
    Ann Pathol; 2009 Nov; 29 Spec No 1():S77-80. PubMed ID: 19887261
    [No Abstract]   [Full Text] [Related]  

  • 40. From traditional molecular biology to network oncology.
    Ziogas DE; Katsios C; Roukos DH
    Future Oncol; 2011 Feb; 7(2):155-9. PubMed ID: 21345133
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.